Breaking News, Collaborations & Alliances

Novo Nordisk, Ascendis Ink $285M GLP-1 Pact

To leverage Ascendis’ TransCon technology platform for once-monthly GLP-1 receptor agonist candidate.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Ascendis Pharma has granted Novo Nordisk an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk products in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in cardiovascular diseases.    The closing of this transaction, subject to regulatory approvals, is expected before the end of 2024.   The agreement includes provisions requiring certain TransCon technology-based produc...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters